Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Terminated(3)

Detailed Status

Withdrawn2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
N/A2 (50.0%)

Trials by Status

active_not_recruiting125%
withdrawn250%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingnot_applicable

CyberKnife Dose Escalation Prostate Cancer Trial

NCT03822494
withdrawnnot_applicable

Hypofractionated Whole Pelvic Radiotherapy of the Prostate

NCT02546427
terminatedphase_2

CyberKnife® for Hepatic Metastases From Colorectal Cancer

NCT01318447
withdrawnphase_3

Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

NCT01318200

Clinical Trials (4)

Showing 4 of 4 trials
NCT03822494Not Applicable

CyberKnife Dose Escalation Prostate Cancer Trial

Active Not Recruiting
NCT02546427Not Applicable

Hypofractionated Whole Pelvic Radiotherapy of the Prostate

Withdrawn
NCT01318447Phase 2

CyberKnife® for Hepatic Metastases From Colorectal Cancer

Terminated
NCT01318200Phase 3

Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4